Histopathologically, hyalinization and necrosis were found in '0B-treated tumours, while tumour tissue injected with saline or saline-containing immunoliposomes showed neither destruction nor necrosis. These results suggest that intratumoral injection of boronated immunoliposomes can increase the retention of '0B atoms by tumour cells, causing tumour growth suppression in vivo upon thermal neutron irradiation. Boron neutron capture therapy (BNCT) with intratumoral injection of immunoliposomes is able to destroy malignant cells in the marginal portion between normal tissues and cancer tissues from the side of 4He generation.
damage to those cells in which boron is located at the time of neutron irradiation. Therefore, it is theoretically possible to kill tumour cells without affecting adjacent healthy cells, if '°B atoms can be accumulated selectively in tumour cells. BNCT has been used clinically in patients with malignant brain tumours (Dom, 1994; Hatanaka and Nakagawa, 1994) and melanoma (Mishima et al, 1989a,b) .
Liposomes are useful drug carriers (Bangham et al, 1965; Hashimoto et al, 1983 ; Konno et al, 1987; Singh et al, 1989; Tomita et al, 1989; Feakes et al, 1993) , and it is possible to carry a large amount of ['°B]compound in a liposome, which may be delivered to a tumour cell. We have reported that '°B atoms delivered by immunoliposomes are cytotoxic to human pancreatic carcinoma cells (AsPC-1) with thermal neutron irradiation in vitro (Yanagie et al, 1991) . Multilamellar vesical immunoliposomes are easily phagocytozed by the reticuloendothelial system (RES), so it is very difficult to accumulate the liposomal contents in the target cancers. Because of this, intravenous injections are no longer used in clinical practice, percutaneous echoic intratumoral injection or transarterial embolization (TAE) are preferred (Hasuike et al, 1992) .
In this report, we prepared ['0B]compound solutions in several concentrations and multilamellar liposomes containing ['0B]-compound or ['0B] immunoliposomes. Intratumoral injection of '°B solutions, boronated liposomes and ['°B] immunoliposomes all inhibited tumour cell growth with thermal neutron irradiation in vivo. The ['°B] immunoliposomes showed the strongest suppression of tumour growth in the '°B treated groups. BNCT with intratumoral injection of immunoliposomes with a high content of ['0B] compound has the ability to destroy malignant cells at the edge of the tumour mass.
MATERIALS AND METHODS Chemicals
The caesium salt of undecahydro-mercaptocloso-dodecaborate (Cs2'°B12H,,SH) was kindly supplied by Shionogi Research Laboratories Co. Ltd. (Osaka, Japan). The solubility of the compound in water was 250 mm at 40°C.
Egg yolk phosphatidylcholine (Egg PC) was a gift from Nippon Fine Chemical Co. (Osaka, Japan). Cholesterol was obtained from Sigma Chemical Co. Ltd. (St Louis, MO, USA). Dipalmitoylphosphatidyl-ethanolamine (DPPE) was from CalbiochemBehring (San Diego, CA, USA). N-hydroxy-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was purchased from Pharmacia Fine Chemicals (Uppsala, Sweden); a stock solution (30 mM) in ethanol was stored at -20°C. Dithiothreitol was obtained from Sigma. 3-(2-pyridyldithio) propionyl-dipalmitoyl-phosphatidylethanolamine (DTP-DPPE) was prepared by reacting SPDP with DPPE as described by Barbet et al (1981) .
Target tumour cells and mice
The human pancreatic carcinoma cell line AsPC-1 (Chen, 1982) , which produces carcinoembryonic antigen (CEA) (Gold and Freedman, 1965) , was obtained from Dainihon Seiyaku Co. Ltd. (Osaka, Japan). AsPC-1 was maintained in RPMI-1640 medium (Hazleton Biologics, Kansas, USA), supplemented with 10% fetal calf serum (Cell Culture Laboratories, Ohio, USA) and 100 ,ug ml-1 kanamycin. All cultures were incubated in air with a high moisture content and 5% carbon dioxide at 370C. The medium was routinely changed three times a week.
Male BALB/c nulnu mice were obtained from Nihon SLC (Shizuoka, Japan) and used at 6-7 weeks of age. In each experiment, mice of similar age and weight were selected. Mice were housed in plastic cages and maintained in an air-conditioned room. The procedures for tumour implantation and sacrifice of the animals were in accordance with approved guidelines of the Institution's Animal Ethics Committee.
Preparation of anti-human CEA monoclonal antibody
Detailed procedures for the preparation of the anti-human CEA monoclonal antibody have been described (Yanagie et al, 1991) . Briefly, a cell clone, 2C-8, which secretes anti-human CEA monoclonal antibody, was established from somatic cell hybrids between mouse myeloma cells (X63, Ag8 and 653) and spleen cells of a BALB/c mouse that was hyperimmune to AsPC-1. The 2C-8 Ig G antibody was purified on a DEAE-52 cellulose column. The epitope recognized by the antibody was confirmed to be the 200-kDa CEA and 45-kDa non-specific cross-reacting antigen (NCA) by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting.
Preparation of liposomes containing [10B]compound
Egg yolk PC (5 ,umol), cholesterol (5 ,umol) and DTP-DPPE (0.25 ,umol) were dissolved in chloroform-methanol (2:1) and mixed in a conical flask. The organic solvent was removed by evaporation at 40°C. An aliquot of 0.5 ml of 250 mM ['0B]compound (Cs2'°B,2 H,USH) solution was added to the dried lipid film, and multilamellar vesicles were prepared by vortex dispersion (Tomita et al, 1989) . Uncapsulated ['0B]compound was removed by centrifugation at 20 000 g.
Conjugation of the monoclonal antibody to the liposomal surface
Liposomes were centrifuged at 20 000 g after treatment for 30 min at room temperature with 20 mm dithiothreitol to ensure functional SH-groups (Yanagie et al, 1991) . A sample of 1 ml of monoclonal antibody (4.0 mg ml-') was incubated with an excess amount of SPDP for 30 min at room temperature. After removal of free SPDP by passage through a Sephadex G 25 column, liposomes were suspended in the antibody solution. Following incubation at 4°C overnight, the boronated immunoliposomes were washed by centrifugation at 20 000 g and suspended in 1 ml of 10 mM veronal buffer, pH 7.4, supplemented with 0.4% gelatin (Yanagie et al, 1991) . A prompt-gamma boron analysis technique was used to measure the 478 keV y-photons produced during the '°B (n, a) 7Li reaction; this determines the boron content conjugated with anti-CEA monoclonal antibody and entrapped in liposomes and immunoliposomes (Kobayashi and Kanda, 1983) .
Gamma-irradiation of cells
Cells irradiated with thermal neutrons were also irradiated with various doses of gamma rays generated concomitantly and dependent on the neutron dose. Detailed procedures for the estimation of the effect of gamma rays generated by thermal neutrons have been described (Yanagie et al, 1991) . Briefly, AsPC-1 cells were exposed to gamma rays from a 137Cs source in a Gamma Cell 40 (Atomic Energy of Canada, Ottawa, Canada) equivalent to the fluences of thermal neutron irradiation in an atomic reactor (ICRU, 1964) . After irradiation, 0.25 ,uCi [3H]TdR was added to each well and incubated for 8 h. The incorporated thymidine was quantified in a liquid scintillation spectrometer. Thermal neutron fluences (2 x 1012 and 5 x 1012 n cm-2) generated 1.03 and 3.36 Gy of gamma ray, respectively, in the thermal column of the TRIGA-II reactor. Doses less than 1.03 Gy of gamma rays had no inhibitory effect on AsPC-1 cell growth. Since the growth of AsPC-1 cells was weakly suppressed by 3.36 Gy gamma ray, thermal neutron fluences less than 2 x 10l2 n cm-2 were used in the in vivo experiment.
Thermal neutron irradiation In vitro experiments
Detailed procedures for boron neutron capture have been described previously (Yanagie et al, 1991 In vivo experiments AsPC-1 cells (1 x 107) were injected subcutaneously into the back of male BALB/c nu/nu mice. At 10-14 days after injection, when the estimated tumour weight reached 100-300 mg, 0.2 ml of 10B solution (0, 500, 1000, or 2000 p.p.m.), boronated liposomes or boronated immunoliposomes were injected directly into the tumours. One hour after injection, mice were irradiated for 37 min with 9 x 108 ns-1 cm2 thermal neutrons (total fluence: 2 x 1012 n cm-2) at the TRIGA-II atomic reactor. After irradiation, the effect of BNCT was evaluated on the basis of tumour volume (calculated as 1/2 x length x width2) and histological findings of the tumours at 3-day intervals (Konno et al, 1987) . Boron concentrations of tumours and blood were analysed by prompt-gamma boron analysis technique (Kobayashi and Kanda, 1983) .
RESULTS

Growth inhibition of tumour treated with '0B solutions
In order to examine the therapeutic effect of '°B solutions on the growth of AsPC-l cells, tumour-bearing mice (n = 10) were injected intratumorally with '0B solutions. The concentrations of '°B solutions were 0 (control, saline), 500, 1000 and 2000 p.p.m. After injection, mice were irradiated with 2 x 1012 n cm-2 thermal neutrons. As shown in Figure IA , significant inhibition of tumour growth was observed in all three groups treated with '°B solutions compared with the control group. The inhibition was dose dependent. mice were irradiated with 2 x 1012 n cm-2 thermal neutrons. As shown in Figure 3B, (Gabizon and Papahadjopoulos, 1988) . Administration of liposomes in vivo is usually non-toxic (Hughes et al, 1989) , since they are composed of biodegradable lipids. Immunoliposomes targeted to a specific organ may deliver a high concentration of the encapsulated drug to the organ . Drugs released from immunoliposomes can reach target cells by free diffusion over a relatively short distance, thereby producing a localized high dose essential for cytotoxicity. The immunoliposome could serve as a local depot for sustained drug release. An increase in the number of antibody molecules per liposome will prolong the retention of the immunoliposome in the target organ (Hughes et al, 1989) .
In BNCT is dependent on the absolute amount and location of boron in the tumour as well as the tumour-blood and tumournormal tissue boron concentration ratios. Effective BNCT requires the delivery of a considerable amount (> 15 p.p.m.) of '0B into the targeted malignant tissue (Coderre et al, 1990) . Selective tissue cytotoxicity can be achieved in tissues containing '°B that receive irradiation with thermal neutrons. a-Particles and 7Li recoil nuclei have a very high linear energy transfer, resulting in the rapid transfer of their energy to cells within a diameter of approximately 12 gm. This energy transfer is highly destructive to critical molecular targets, such as nuclear DNA. Therefore, it is desirable to achieve a high gradient between the '°B concentration in tumour compared with adjacent healthy tissues.
Studies in animal models indicate that tumour uptake after administration of the sulphydryl borane dimer (Na410B24H22S2 is about twice the tumour uptake after administration of equal amounts of boron as a monomer (Joel et al, 1989 . It was observed that the decrease in tumour boron concentration is much slower after infusion of dimer than with monomer. Mercaptoundecahydrododecaborate sodium (Na2'B 12 H1SH; BSH) may be oxidized to a dimer and react with disulphide-containing proteins. Joel et al (1989 Joel et al ( , 1990 ) measured the '0B concentrations in the tumours by prompt-gamma spectrometry. The boron-containing amino acid analogue, boronophenylalanine (BPA) has been shown to deliver boron selectively to melanoma tissue (Mishima et al, 1989b) . BPA has been successful in animal models and has recently been used in Japan in human trials of BNCT for melanoma (Mishima et al, 1989a) . In a study of BPA distribution in a rat glioblastoma, Coderre et al (1990 Coderre et al ( , 1994 ) demonstrated a tumour-blood ratio of 4:1 compared with 0.7:1 for BSH. Ratios as high as 400:1 in tumour compared with normal brain were obtained 48 h after intravenous injection of 100 mg kg-' BOPP, while at the same time point, the tumour-blood ratio was only 11:1 (Hill et al, 1992; Malleshe et al, 1993) . Damage to brain endothelium may present particular problems, if reactor exposures take place when blood boron levels are high . Thus, it is critical to accumulate ['0B]compound in the tumour mass by intratumoral injection and to avoid raising the concentrations of blood boron.
Most treatment failures are caused by local recurrence of the tumour, suggesting that more aggressive local therapy could be beneficial. BNCT using intratumoral injections of ['°B]immunoliposomes will be useful to control local recurrence with minimal damage to adjacent normal tissue. There are several potential clinical applications of ['0B]immunoliposomes for improving further methods for inhibiting the uptake of intravenously administered immunoliposomes by the reticuloendothelial system (RES). To obviate phagocytosis by the RES, we have tried to prepare polyethylene glycol-coated immunoliposomes (stealth immunoliposomes) (Maruyama et al, 1995) . Experiments using systemic injection of stealth immunoliposomes are in progress for selective targeting of '°B atoms in tumours in the application of clinical BNCT.
